GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential
- Conditions
- Interventions
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04680273
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
- Conditions
- Interventions
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 252
- Registration Number
- NCT04632992
- Locations
- 🇺🇸
Kaiser Permanente - San Leandro Medical Center, San Leandro, California, United States
🇺🇸Ascension St. John Hospital, Detroit, Michigan, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT04607148
- Locations
- 🇺🇸
Southwest Retina Consultants, Durango, Colorado, United States
🇺🇸Florida Eye Associates - Melbourne 2nd Office, Melbourne, Florida, United States
🇺🇸Southeastern Retina Associates Chattanooga, Chattanooga, Tennessee, United States
Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04566003
- Locations
- 🇺🇸
Invicro, a Konica Minolta company, New Haven, Connecticut, United States
Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04539470
- Locations
- 🇺🇸
University of Kansas Med Ctr; Int med/Allgy/Immun/Rheum, Kansas City, Kansas, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT04468607
- Locations
- 🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States
🇦🇺Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, Australia
🇺🇸City of Hope, Duarte, California, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 498
- Registration Number
- NCT04449874
- Locations
- 🇺🇸
UPMC - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Univ of Calif, San Francisco; Breast Cancer Center, San Francisco, California, United States
A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04434469
- Locations
- 🇧🇪
UZ Gent, Gent, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
🇳🇴Oslo Universitetssykehus HF; Ullevål sykehus, Oslo, Norway
An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic
- Conditions
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT04395508
- Locations
- 🇺🇸
Beverly Hills Cancer Center, Beverly Hills, California, United States
🇺🇸University Of Colorado, Aurora, Colorado, United States
🇺🇸Mayo Clinic-Jacksonville, Jacksonville, Florida, United States
A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04394845
- Locations
- 🇺🇸
Invicro, a Konica Minolta company, New Haven, Connecticut, United States